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Abstract
Previous genome-wide expression studies have highlighted distinct gene expression patterns in inflammatory bowel
disease (IBD) compared to control samples, but the interpretation of these studies has been limited by sample
heterogeneity with respect to disease phenotype, disease activity, and anatomic sites. To further improve molecular
classification of inflammatory bowel disease phenotypes we focused on a single anatomic site, the disease unaffected
proximal ileal margin of resected ileum, and three phenotypes that were unlikely to overlap: ileal Crohn’s disease (ileal CD),
ulcerative colitis (UC), and control patients without IBD. Whole human genome (Agilent) expression profiling was conducted
on two independent sets of disease-unaffected ileal samples collected from the proximal margin of resected ileum. Set 1 (47
ileal CD, 27 UC, and 25 Control non-IBD patients) was used as the training set and Set 2 was subsequently collected as an
independent test set (10 ileal CD, 10 UC, and 10 control non-IBD patients). We compared the 17 gene signatures selected by
four different feature-selection methods to distinguish ileal CD phenotype with non-CD phenotype. The four methods
yielded different but overlapping solutions that were highly discriminating. All four of these methods selected FOLH1 as a
common feature. This gene is an established biomarker for prostate cancer, but has not previously been associated with
Crohn’s disease. Immunohistochemical staining confirmed increased expression of FOLH1 in the ileal epithelium. These
results provide evidence for convergent molecular abnormalities in the macroscopically disease unaffected proximal margin
of resected ileum from ileal CD subjects.
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Introduction
Transcriptomic analyses have highlighted differences in intes-
tinal gene expression patterns between samples collected from
patients with inflammatory bowel disease (IBD) compared to
control patients without inflammatory bowel disease [1–11].
Differences in transcript levels, particularly those involved in
inflammatory pathways, have been observed in macroscopically
disease affected regions of the intestine compared to disease-
unaffected regions of the intestine [6]. Molecular characterization
of inflammatory bowel disease phenotypes based on transcrip-
tomic analysis has been limited by sample heterogeneity with
respect to disease phenotype, disease activity and anatomic sites.
Most of the previous studies have focused on the colon, since this
anatomic site is more easily accessible by colonoscopy.
We have previously examined genome wide expression profiles
in the disease unaffected proximal margin of resected ileum
collected from 4 patients with Crohn’s disease of terminal ileum
(ileal CD) undergoing initial ileocolic resection with that of 4
control non-IBD patients undergoing initial right hemicolectomy
or total colectomy [8]. We have focused on the ileal CD phenotype
and excluded subjects with Crohn’s Colitis, sincethese two
subphenotypes have distinct molecular characteristics [12].
Increased expression of candidate genes such as MUC1, DUOX2
and DMBT1 expression and decreased expression of C4orf7
(follicular dendritic cell secreted peptide) was confirmed by reverse
transcriptase polymerase chain reaction of 18 ileal CD and 9
control non-IBD samples. We found that these alterations in gene
expression were independent of NOD2 genotype [8].
To better define the molecular characteristics of the ileal CD
phenotype, we applied four different feature selection methods to
select 17-gene signatures that would distinguish samples of the
proximal disease unaffected proximal margin of ileum that were
resected from individuals with ileal CD phenotype, from samples
collected from non-CD phenotype (both non-IBD and ulcerative
colitis patients) to a training set composed of 99 expression profiles.
We then tested these features in an independently collected test set
of 30 expression profiles.
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Patients and Acquisition of Ileal Tissue Samples
This study was approved by the Washington University-St.
Louis and Stony Brook University Institutional Review Boards.
Ileal CD patients undergoing ileocolic resection, UC patients
undergoing total colectomy and Control non-IBD patients
undergoing either right hemicolectomy or total colectomy (for
colon cancer, colonic adenomas, colonic inertia, diverticulosis and
one case of a foreign body with perforation) were prospectively
enrolled in a consecutive fashion by the Washington University
Digestive Diseases Research Core Center Tissue Procurement
Facility to donate surgically resected tissue samples between
September 2005 and December 2010. A subset of 8 of the 99
expression profiles generated from samples collected between
September 2005 and February 2010 in the training set were
previously reported [8]. A subset of 81 of 99 expression profiles in
the training set (Set 1) were previously reported in a study linking
ileum associated microbial composition with cluster centroids
corresponding to a cluster enriched in genes expressed in Paneth
cells and two clusters enriched in genes associated with xenobiotic
metabolism [11], [13]. The 30 expression profiles in the test set
(Set 2) were collected from additional subjects recruited between
February 2010 and December 2010. The diagnosis of CD or UC
was based on the surgical pathological report for the surgical
resection specimen, which was issued by the attending surgical
pathologist assigned to the case. Patients who were unwilling or
unable to give informed written consent were excluded. At least 4
ex-vivo biopsies were collected from the macroscopically disease-
unaffected proximal margin of the freshly resected pathologic
ileum specimens using Radial Jaw4 large-capacity biopsy forceps
(Boston Scientific, Natick, MA) and placed immediately into
RNAlater, an RNA stabilization solution, and stored at -80uC.
The designation of disease-unaffected was based on the macroscopic
appearance of the ileal mucosa and the surgical pathology report
of adjacent ileal biopsies (‘‘no histopathologic abnormality’’). The
clinical information and samples were collected as previously
described [11], [13] and stripped of all identifying information and
assigned both a patient code and sample code. All of the patients
received intravenous antibiotic prophylaxis covering both aerobic
and anerobic bacteria (e.g. ciprofloxacin and metronidazole,
cefoxitin, cefotetan) within one hour of incision [14].
Microarray Analysis
Total RNA was extracted from the tissue samples using TRI
ReagentH according to the manufacturer’s recommendation, and
RNA quality was assessed using an Agilent 2100 Bioanalyzer [8].
The test RNAs and a common reference ileal RNA were labeled
with the Quick Amp Labeling Kit (Agilent No. 5190-0424) and
the resulting probes were hybridized to Agilent Whole Human
Genome Arrays (Agilent No. G4412A) as previously described [8],
[9]. The pre-processing, filtering and normalization of the
microarray data was conducted using the R package LIMMA
[15], [16] Probes with all Genepix flags less than 2100 were
treated as absent and removed from the dataset. There were
technical duplicates on three samples in the training set and two
samples in the test set. For those samples, the log2 ratios for the
technical duplicates were averaged prior to analysis. The data
discussed in this publication have been deposited in NCBI’s Gene
Expression Omnibus and are accessible through GEO Series
accession number GSE24287 (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE24287).
Statistical Analysis
Two-class (ileal CD vs. non-CD) unpaired significance analysis
of microarrays (SAM) was performed on 25,756 probes in the
training set as previously described by Tusher et al [17] as an initial
filtering step (.1.5 fold, ,0.67 fold, FDR ,0.05). SAM assigns a
gene-specific t-test (q-value) based on changes in gene expression
relative to the standard deviation of repeated measurements for
that gene. Feature subset selection of 17-gene signatures was
performed on the resulting 464 probes selected by SAM using the
following four methods: Component-wise Boosting (Boosting) [18],
Prediction Analysis of Microarrays (PAM) [19], Random Forest
[20] and Least Absolute Shrinkage and Selection Operator
(LASSO) [21]. In order to evaluate the four different feature
selection methods, a majority vote [22] based on the median score
of seven supervised machine learning tools, Boosting [18], PAM
[19], Random Forest [20], LASSO [21], Support Vector Machine
[23], Linear Discriminant Analysis [24], Naive Bayes [25]), was
performed. The overall accuracy, sensitivity, specificity and area
under the curves (AUC) were initially calculated based on the
empirical receiver operating characteristic (ROC) curves [26]. The
ROC curves were then smoothed to facilitate visual differentiation
as previously described [27]. Partial correlation network analysis
based on the joint sparse regression models [28] was further
conducted to study the network relationship among the 17 gene
signature selected by the boosting method.
Immunohistochemistry
Folate hydrolase 1 (FOLH1), also termed prostate specific
membrane antigen (PSMA) [29], expression in formalin fixed
paraffin embedded sections of the disease unaffected proximal
margin of resected ileum from ileal CD patients and Control non-
IBD patients, were stained using a monoclonal mouse anti-PSMA
antibody (clone E6, catalog number N1611, DAKO) in the
Washington University Digestive Diseases Research Core Center
Morphology Core. Epitope retrieval was performed with the Diva
DECLOAKER reagent (BIOCARE DV-2004) in a Biocare
Decloaking chamber. Primary antibody was applied overnight at
4uC at a dilution of 1:500. Antigen antibody complexes were
detected with biotinylated goat anti-mouse IgG (1:2000, Jackson
Laboratories), then developed in diaminobenzimidine (Biocare
Betazid DAB) and counterstained with hematoxylin. Negative
control slides were incubated with isotype-matched immunoglob-
ulin, and a prostatic adenocarcinoma specimen served as a positive
control for staining with the anti-PSMA (FOLH1) antibody.
Results
Patient Characteristics in the Training and Test Sets (see
Table 1)
The patients included in this study were predominantly white.
As shown in Table 1, C. difficile was more prevalent among UC
patients than ileal CD or control non-IBD patients [30], [31].
None of the control subjects were treated with5-ASA, immuno-
modulators, and/or anti-TNFa biologics. However all of the
patients received intravenous antibiotic prophylaxis that covered
both aerobic and anaerobic bacteria within one hour prior to
incision [14].
Two-Class Unpaired Significance Analysis of Microarrays
(SAM) Comparing Ileal CD and Non-CD (UC and control
non-IBD) Phenotypes (see Table S1)
Because a large amount of variability can be introduced in the
fold change for low intensity signals, the threshold for gene filtering
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25,676 gene-probes [32]. Two-class unpaired SAM analysis
comparing ileal CD with non-CD phenotype was performed as
the initial filtering step, and identified 464 gene probes (see Table
S1) that were differentially expressed (fold change $1.5 or #0.67,
FDR ,0.05) between ileal CD and Non-CD (UC and Control)
samples [17]. In this training set of 99 microarrays, the mean
DMBT1 expression level was confirmed to be significantly
increased, while that of C4orf7 was confirmed to be significantly
decreased in the disease unaffected proximal margin of ileum
resected from ileal CD patients compared to nonIBD Control and
UC patients [8]. We also observed that MUC1 and DUOX2
expression was increased relative to Control samples. However
because MUC1 and DUOX2 expression was also increased in UC
compared to nonIBD Control samples, these genes were not
selected in this two-class unpaired SAM comparing ileal CD and
non-CD (UC and Control).
Feature Subset Selection (see Table S2)
Four feature subset selection methods (Boosting [18], PAM [19],
Random Forest (RF) [20], and LASSO [21]), were applied to
further select subsets of 17 gene probes or features that were useful
for predicting the ileal CD phenotype. The union of the resulting
four 17-gene signatures totaled 42 in number (see Table S2)
because 26 of the features were selected by more than one
method.Folate hydrolase 1 (FOLH1) gene was selected by all four
feature selection methods. Three known genes, TLR4 interactor
with leucine rich repeats (TRIL), Niemann-Pick disease, type C1,
gene-like 1 (NPC1L1), and C4orf7 also termed follicular dendritic
cell secreted protein were selected by three of the four methods.
Six known genes were selected by two of four methods, BCL2-
associated X protein (BAX), cytochrome P 450, family 26,
subfamily B, polypeptide 1 (CYP26B1), nephronectin (NPNT),
protein phosphatase 1, regulatory (inhibitor) subunit 14A
(PPP1R14A), family with sequence similarity129, member C
(FAM129C) also termed B-cell novel protein 1 (BCNP1), cathe-
licidin antimicrobial peptide (CAMP), chemokine (C-C motif)
ligand 23 (CCL23). We repeated our analysis using data excluding
the C. difficile positive samples. FOLH1 is still the only gene probe
selected by all four feature selection methods and it is still ranked
prominently by all four classifiers 2
nd, 1,st, 1
st and 4
th by PAM,
RF, LASSO and Boosting, respectively). In addition, ten out of 12
Table 1. Patient characteristics associated with each disease phenotype in the training and test sets.
Training Set
Variables Ileal CD (n=47) UC (n=27) Control (n=25)
Gender (male) 43% 59% 32%
Race (white) 96% 100% 96%
Median Age (range) y 35 (20–75) 43 (17–64) 55 (18–84)
Current smoker 32% 10% 24%
Positive fecal C. difficile toxin 0% 30% 0%
Median BMI (range) kg/m
2 24 (16–38) 24 (18–43) 28 (20–38)
5-ASA 55% 63% 0%
Steroids 43% 67% 0%
Immunomodulators 45% 44% 0%
Anti-TNFa biologics
Current (#8 weeks of surgery) 28% 41% 0%
Past (.8 weeks of surgery) 8% 7% 0%
Never 64% 52% 0%
Test Set
Variables Ileal CD (n=10) UC (n=10) Control (n=10)
Gender (male) 40% 70% 40%
Race (white) 90% 90% 100%
Median Age (range) y 39 (19–58) 44 (16–62) 66 (21–77)
Current smoker 20% 20% 40%
Positive fecal C. difficile toxin 0% 30% 0%
Median BMI (range) kg/m
2 22 (19–39) 24 (20–33) 25 (20–36)
5-ASA 40% 80% 0%
Steroids 70% 100% 0%
Immunomodulators 40% 30% 0%
Anti-TNFa biologics
Current (#8 weeks of surgery) 40% 20% 0%
Past (.8 weeks of surgery) 0% 0% 0%
Never 60% 80% 0%
doi:10.1371/journal.pone.0037139.t001
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without C. difficile positive samples overlap with those selected
using data including the C. difficile positive samples. Meanwhile,
the Bossting method still features the highest classification
accuracy at 89.90% and 86.96% for data with and without the
C. difficile positive samples, respectively. All these observations
indicate that our method was not skewed by the C. difficile toxin
factor.
Majority vote based on the median score of seven classifier tools
(see Materials and Methods) was used to assess the accuracy
associated with each feature subset for ileal CD phenotype in the
training set via Jack-Knife (take-one-out) cross validation. The
feature subset selected by the boosting method yielded the highest
area under the curve (AUC) and overall accuracy (see Table 2).
The smoothed receiver operating characteristic (ROC) curves for
the seven classifiers as well as their majority vote based on the
training data were comparable (see Figure 1). We then applied this
17 gene signature to an independent test set that was collected
after the training set (see Figure 2, Table 3). As shown in Table S2,
the polarity of the mean fold change for this 17 ileal gene signature
was preserved in both the training and test set. Of note, errors in
classification reflected misclassification of UC samples as ileal CD
samples. The smoothed ROC curves are shown in Figure 2 in
order to facilitate visual differentiation of the different classifiers.
There was good agreement between the AUC for the empirical
and smoothed ROC curves (see Table S3), indicating that the
smoothed ROCs retained the key properties of the empirical
ROCs.
FOLH1 is a ‘‘Hub’’ Gene by Partial Correlation Network
Analysis
Partial correlation network analysis was conducted on the union
of the features selected by the four methods using all 129
microarrays in both the training and test set to assess the
coregulation of these 42 genes. As shown in Figure 3, the folate
hydrolase 1 (FOLH1) gene was identified as a ‘‘hub’’ gene that has
significantly non-zero partial correlations to 12 of the other 16
gene biomarkers (see Figure 3). The FOLH1 gene was originally
identified as a prostate specific membrane antigen detected as
upregulated in prostate carcinoma [33], however expression of
FOLH1 has since been observed in other tissues including the small
intestine, particularly in the duodenal mucosa, the nervous system
and the kidney [34]. Because FOLH1 expression has been
observed in neoplastic and nonneoplastic neovasculature [35],
immunochemical localization of FOLH1 was performed on the
disease unaffected proximal margin of resected ileum from ileal
CD and control non-IBD subjects. A representative micrograph is
shown in Figure 4, which demonstrates that the more prominent
staining in ileal CD samples was localized to the villous epithelium.
Discussion
In this study, we took a statistical approach to identify ileal gene
biomarkers associated with ileal CD phenotype compared to non-
CD (UC and control). Some of the genes (e.g. DUOX2 and MUC1)
that we noted previously to be upregulated in ileal CD with control
non-IBD subjects were not selected in the current study because
these genes were also upregulated in UC compared to control
samples [8]. Feature selection is one of the most important issues
in classification. In this study, four feature selection methods,
(Boosting, PAM, Random Forest and LASSO), were applied to
select subsets of 17 gene features. The four methods yielded
different but overlapping solutions that were highly discriminating.
Thus, feature selection with microarray data can lead to different
solutions that are comparable with respect to prediction rates.
Note that different underlying hypotheses are associated with each
method in selecting features from an extremely large number of
variables in the microarray datasets compared to the number of
samples [36,37]. Combining different methods has been used as an
approach to improve classification performance [38,39].
All four selection methods identified upregulation of FOLH1
expression as predictive of the ileal CD phenotype compared to
non-CD. FOLH1 encodes a transmembrane glycoprotein that acts
Figure 1. Receiver operating characteristic (ROC) curve for different classification methods on the training set.
doi:10.1371/journal.pone.0037139.g001
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Immunohistochemical staining localized more prominent expres-
sion of this gene in ileal CD samples to the villous epithelium [34].
Of the features selected by alternative feature selection methods
(see Table 2), only FOLH1B clustered with FOLH1 in the training
dataset [11]. FOLH1 is an established biomarker for prostate
cancer, but has not been previously identified as a biomarker for
Crohn’s disease.
Three genes, TRIL, NPCL1 and C4orf7 were selected by three of
four of the feature selection methods. TRIL, was recently identified
as a novel component of the TLR4 complex and TLR3 complex
[40], [41]. TRIL mRNA expression has been detected in the small
intestine, as well as the central nervous system, lung, kidney and
ovary. TRIL expression is upregulated in cell culture by
lipopolysaccharide. The upregulation of TRIL expression could
reflect altered host microbial interactions in macroscopically
disease unaffected regions of the intestine in ileal CD patients.
NPC1L1 is required for intestinal uptake of cholesterol and plant
Figure 2. Receiver operating characteristic (ROC) curve for different classification methods on the test set.
doi:10.1371/journal.pone.0037139.g002
Table 2. Comparison of 17 ileal gene signatures selected by
four different feature selection methods.
Methods AUC Accuracy
Boosting 0.928 89.9%
PAM 0.895 88.9%
Random forest 0.902 85.9%
LASSO 0.895 85.9%
Boosting [16], PAM) [17], random forest [18] and LASSO [19] were applied to the
SAM filtered training microarray dataset to select 17 ileal gene signatures. The
AUC and overall accuracy for each of the signatures were calculated based on
the majority vote of 7 classifiers (Boosting, PAM, Random Forest, LASSO,
Support Vector Machine, Linear Discriminant Analysis, and Naive Bayes), which
is equivalently to the decision based on the median score using an usual
probability threshold of 0.5 (see Materials and Methods).
doi:10.1371/journal.pone.0037139.t002
Table 3. Classification results on the training and test sets.
Classification Method Accuracy Sensitivity Specificity
Training Set
Support Vector Machine (SVM) 90.9% 91.5% 90.4%
Random Forest (RF) 86.9% 87.2% 86.5%
Linear Discriminant Analysis (LDA) 90.9% 89.4% 92.3%
Predictive Analysis of Microarray
(PAM)
88.9% 89.4% 88.5%
Lasso 91.9% 91.5% 92.3%
Boosting 88.9% 89.4% 88.5%
Naı ¨ve Bayes 88.9% 89.4% 88.5%
Majority Vote (Combined
Classifiers)
89.9% 91.5% 88.5%
Test Set
Support Vector Machine (SVM) 83.3% 80.0% 85.0%
Random Forest (RF) 73.3% 90.0% 65.0%
Linear Discriminant Analysis (LDA) 76.7% 80.0% 75.0%
Predictive Analysis of Microarray
(PAM)
86.7% 100.0% 80.0%
Lasso 86.7% 80.0% 90.0%
Boosting 86.7% 90.0% 85.0%
Naı ¨ve Bayes 83.3% 100.0% 75.0%
Majority Vote (Combined
Classifiers)
80.0% 90.0% 75.0%
The accuracy, sensitivity, specificity of the ileal gene signature selected by the
boosting method [16] are calculated using Leaving-One-Out cross validation on
the training and subsequently, direct classification of the test set based on the
training set.
doi:10.1371/journal.pone.0037139.t003
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Upregulation of NPC1L1 expression in ileal CD patients may also
contribute to enhanced atherogenesis in Crohn’s patients [44].
Partial correlation network analysis revealed that FOLH1 has
nonzero correlations with 12 of the other 16 genes in the signature.
The biological basis for the nonzero partial correlations between
the ‘‘hub’’ gene, FOLH is not immediately apparent.
We have previously noted downregulation of C4orf7 as well as
other genes associated with organized lymphoid structures and/or
B-cell function in ileal CD patients compared to non-IBD control
patients [8]. This study indicates that downregulation of ileal
C4orf7 expression is also observed in ileal CD patients, when
compared with UC patients.
Partial correlation network analysis revealed that FOLH1 has
nonzero correlations with 12 of the other 16 genes in the signature.
The biological basis for the nonzero partial correlations between
the ‘‘hub’’ gene, FOLH is not immediately apparent. Thus far, we
have not detected association of the gene features listed above with
alterations in microbial composition, but we are likely underpow-
ered to detect such associations with only 81 samples with paired
microbiome and microarray data [11]. We also noted that
upregulation of FOLH1 was observed in ileal CD samples
regardless of NOD2 genotype [8].In this study we report the
results of binary classification – ileal CD vs. non-CD. Our attempts
to apply multiclassification to the data set yielded poor accuracy
particularly between the UC and control non-IBD phenotypes.
This may be partly because the number of UC samples and
control non-IBD samples were both smaller than the number of
ileal CD samples. Of note, the errors in the binary classification of
ileal CD vs. non-CD reflected misclassification of two UC samples
as ileal CD. In the original test set we had an additional sample
from a subject with a pre-operative diagnosis of UC. However the
Figure 3. Partial correlation network among the 17 selected genes. FOLH1 is linked to multiple genes and serves as a hub gene. A red line
between genes indicates a positive non-zero partial correlation and a blue line indicates a negative non-zero partial correlation.
doi:10.1371/journal.pone.0037139.g003
Figure 4. Immunohistochemical localization of FOLH1 in
disease unaffected ileal mucosa from the proximal margin of
resected ileum from an ileal CD subject (left panel) and a
control non-IBD subject. The more prominent FOLH1 staining in the
ileal CD sample is localized to the villous epithelium. Magnification is
1006. Bar is 200 mm.
doi:10.1371/journal.pone.0037139.g004
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the pathological diagnosis of the resected specimen. Interestingly
this discarded sample was classified as ‘‘ileal CD’’ based on the
expression profile. While the ileal CD phenotype can be easily
distinguished from ulcerative colitis based on imaging and
endoscopic findings, it is more difficult to distinguish Crohn’s
colitis from ulcerative colitis even after pathological diagnosis of
the resected colon [45]. Improving our ability to distinguish UC
from Crohn’s colitis at the time of the initial colon resection would
improve clinical decision making with respect to performing a
subsequent ileal pouch anal anastomosis [46]. For this reason we
are continuing to follow our UC patients after colectomy to
determine whether any of these patients are diagnosed subse-
quently as Crohn’s disease. We also plan to begin analyzing
disease unaffected ileal samples collected from patients undergoing
colectomy for Crohn’s colitis to determine whether there is any
overlap in the ileal signature for ileal CD and Crohn’s colitis.
In summary, we have identified potential biomarkers for ileal
CD phenotype in the macroscopically disease unaffected proximal
margin of resected ileum from ileal CD subjects. These results
provide evidence for convergent molecular abnormalities in the
macroscopically disease unaffected proximal margin of resected
ileum from ileal CD subjects,
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